This federal contract award is a delivery order issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract is for the supply of NEXPLANON 68 MG IMPLANTS, with a ceiling value of $7,146.90 and a period of performance through September 27, 2024.
The award is part of a larger indefinite delivery contract (IDC) valued at up to $499,999,999 that DMS Pharmaceutical Group holds with the DLA under the SPE2DB program. This single-award IDC allows the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items to fulfill the recurring medical supply needs of military health facilities worldwide. DMS Pharmaceutical Group is a key supplier in the federal pharmaceutical supply chain, providing a variety of medications and medical supplies to the Department of Defense (DoD) and Department of Veterans Affairs (VA).
Generated 12/6/24, 9:03 AM